Wigen Biomedicine
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage Chinese biotech developing novel small molecule oncology drugs using covalent, PROTAC, and conjugation platforms.
OncologyImmunology
Technology Platform
Integrated platform for novel small molecule modalities including covalent/allosteric inhibitors, PROTAC protein degraders, and drug conjugation technologies.
Opportunities
Potential to address undruggable targets through PROTAC and covalent inhibitor platforms, with multiple clinical-stage assets that could attract partnership or licensing deals from global pharma.
Risk Factors
Heavy competition in oncology small molecule space, undisclosed clinical data makes pipeline evaluation difficult, and dependence on continued funding to advance multiple early-stage programs.
Competitive Landscape
Competes with other Chinese oncology-focused biotechs like Jacobio, Cullgen, and global PROTAC players like Arvinas; differentiation through integrated platform combining covalent, allosteric, and conjugation approaches.